Current treatment landscape and translational priorities in malignant rhabdoid tumor of the kidney - Top-Institutions - MDSpire

Current treatment landscape and translational priorities in malignant rhabdoid tumor of the kidney

  • By

  • Zhigang Yao

  • Chenghao Zhanghuang

  • Nian Zhou

  • Jinrong Li

  • Zipeng Hao

  • Bing Yan

  • Hui Zhao

  • June 10, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    St. Jude Children’s Research Hospital
    St. Jude Children’s Research Hospital

    Memphis, Tennessee

    Key Differentiators

    • Pediatric Oncology

  • #2

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Pediatric Oncology

  • #3

    Children’s Oncology Group
    Children’s Oncology Group

    Los Angeles, California

    Key Differentiators

    • Pediatric Oncology

Original Source(s)

Current treatment landscape and translational priorities in malignant rhabdoid tumor of the kidney

  • by Zhigang Yao, Chenghao Zhanghuang, Nian Zhou, Jinrong Li, Zipeng Hao, Bing Yan, Hui Zhao

  • June 10, 2026

Related Content

Harnessing Vδ1+ T cells for next-generation immunotherapy: from mechanistic insights to clinical translation

Editorial: Metabolic cell death in cancer: innovative therapeutic avenues for cancer treatment

Hetairos is a histology-based artificial intelligence model for predicting central nervous system tumor methylation subtypes